These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37398992)

  • 1. Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.
    Akshintala S; Sundby RT; Bernstein D; Glod JW; Kaplan RN; Yohe ME; Gross AM; Derdak J; Lei H; Pan A; Dombi E; Palacio-Yance I; Herrera KR; Miettinen MM; Chen HX; Steinberg SM; Helman LJ; Mascarenhas L; Widemann BC; Navid F; Shern JF; Heske CM
    Clin Cancer Res; 2023 Sep; 29(17):3329-3339. PubMed ID: 37398992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
    Secord AA; Teoh DK; Barry WT; Yu M; Broadwater G; Havrilesky LJ; Lee PS; Berchuck A; Lancaster J; Wenham RM
    Clin Cancer Res; 2012 Oct; 18(19):5489-98. PubMed ID: 22837181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
    Somlo G; Atzori F; Strauss LC; Geese WJ; Specht JM; Gradishar WJ; Rybicki A; Sy O; Vahdat LT; Cortes J
    Clin Cancer Res; 2013 Apr; 19(7):1884-93. PubMed ID: 23403636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma.
    Shulman DS; Merriam P; Choy E; Guenther LM; Cavanaugh KL; Kao PC; Posner A; Bhushan K; Fairchild G; Barker E; Klega K; Stegmaier K; Crompton BD; London WB; DuBois SG
    Cancer Med; 2023 Jul; 12(14):15207-15216. PubMed ID: 37306107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.
    Pappo AS; Vassal G; Crowley JJ; Bolejack V; Hogendoorn PC; Chugh R; Ladanyi M; Grippo JF; Dall G; Staddon AP; Chawla SP; Maki RG; Araujo DM; Geoerger B; Ganjoo K; Marina N; Blay JY; Schuetze SM; Chow WA; Helman LJ
    Cancer; 2014 Aug; 120(16):2448-56. PubMed ID: 24797726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
    van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
    Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
    Mettu NB; Niedzwiecki D; Rushing C; Nixon AB; Jia J; Haley S; Honeycutt W; Hurwitz H; Bendell JC; Uronis H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1025-1035. PubMed ID: 30895346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
    Vlahovic G; Meadows KL; Hatch AJ; Jia J; Nixon AB; Uronis HE; Morse MA; Selim MA; Crawford J; Riedel RF; Zafar SY; Howard LA; O'Neill M; Meadows JJ; Haley ST; Arrowood CC; Rushing C; Pang H; Hurwitz HI
    Oncologist; 2018 Jul; 23(7):782-790. PubMed ID: 29572245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Parseghian CM; Parikh NU; Wu JY; Jiang ZQ; Henderson L; Tian F; Pastor B; Ychou M; Raghav K; Dasari A; Fogelman DR; Katsiampoura AD; Menter DG; Wolff RA; Eng C; Overman MJ; Thierry AR; Gallick GE; Kopetz S
    Clin Cancer Res; 2017 Aug; 23(15):4146-4154. PubMed ID: 28280091
    [No Abstract]   [Full Text] [Related]  

  • 11. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
    Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
    Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
    Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
    BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
    Kato S; Jardim DL; Johnson FM; Subbiah V; Piha-Paul S; Tsimberidou AM; Falchook GS; Karp D; Zinner R; Wheler J; Janku F; Fu S; Lim J; Bean S; Nguyen L; Urban S; Browne E; Meric-Bernstam F; Hong DS
    Invest New Drugs; 2018 Jun; 36(3):416-423. PubMed ID: 29047029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
    Cash T; Jonus HC; Tsvetkova M; Beumer JH; Sadanand A; Lee JY; Henry CJ; Aguilera D; Harvey RD; Goldsmith KC
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30405. PubMed ID: 37158620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
    Okusaka T; Ikeda M; Fukutomi A; Kobayashi Y; Shibayama K; Takubo T; Gansert J
    Jpn J Clin Oncol; 2014 May; 44(5):442-7. PubMed ID: 24782485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
    Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
    J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
    Rosen LS; Puzanov I; Friberg G; Chan E; Hwang YC; Deng H; Gilbert J; Mahalingam D; McCaffery I; Michael SA; Mita AC; Mita MM; Mulay M; Shubhakar P; Zhu M; Sarantopoulos J
    Clin Cancer Res; 2012 Jun; 18(12):3414-27. PubMed ID: 22510349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.
    Murakami H; Doi T; Yamamoto N; Watanabe J; Boku N; Fuse N; Yoshino T; Ohtsu A; Otani S; Shibayama K; Takubo T; Loh E
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):407-14. PubMed ID: 22810805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
    Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
    Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial.
    Cardin DB; Goff LW; Chan E; Whisenant JG; Dan Ayers G; Takebe N; Arlinghaus LR; Yankeelov TE; Berlin J; Merchant N
    Invest New Drugs; 2018 Jun; 36(3):442-450. PubMed ID: 28990119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.